Clinical Trial Update: Study of Xeloxiri Regimen for Patients With Refractory Metastatic Colorectal Cancer [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating the Xeloxiri regimen for patients with refractory metastatic colorectal cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer

Drugs mentioned

• Camptosar (irinotecan)
• Eloxatin (oxaliplatin)
• Xeloda (capecitabine)

Snippet

Sponsor: The University of Hong Kong | Conditions: Colorectal Cancer | Phase 2 | Status: COMPLETED